{
    "nctId": "NCT04629846",
    "briefTitle": "Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.",
    "officialTitle": "A Randomized, Multicenter, Double-Blind, Parallel-Controlled, Phase III Clinical Study to Evaluate QL1209/Pertuzumab in Combination With Docetaxel in Patients With Early-Stage or Locally Advanced HER2-Positive and ER/PR-negative Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 517,
    "primaryOutcomeMeasure": "Total pathologic complete response (tpCR) rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Volunteer to participate in this clinical study; Completely understand and know this study as well as sign the informed consent form (ICF);\n2. Age \u2265 18 years and \u2264 80 years when ICF is signed;\n3. Histologically confirmed invasive breast carcinoma with a primary tumor size of more than (\\>) 2 centimeters (cm) by standard local assessment technique; Breast cancer stage at presentation: early-stage (T2-3, N0-1, M0) or locally advanced (T2-3, N2 or N3, M0; T4, any N, M0); HER2-positive breast cancer confirmed by immunohistochemistry or HER2 gene amplification by in situ hybridization; Estrogen receptor and Progesterone receptor negative.\n4. Eastern Cooperative Oncology Group Performance Status equal to or less than (\\<=) 1.\n5. Baseline left ventricular ejection fracture \\>= 55% measured by echocardiography (preferred) or multiple gated acquisition scan\n\nExclusion Criteria:\n\n1. Stage IV metastatic breast cancer;\n2. Inflammatory breast cancer;\n3. Previous anti-cancer therapy or radiotherapy for any malignancy;\n4. History of malignancies other than colorectal cancer within 5 years prior to randomization, excluding cutaneous basal cell carcinoma, cervical carcinoma in situ, and thyroid papillary adenocarcinoma of non-melanoma after radical treatment;\n5. Concurrent anti-cancer treatment in another investigational trial, including hormone therapy, bisphosphonate therapy, or immunotherapy;\n6. Major surgical procedure within 4 weeks prior to randomization or from which the participant has not fully recovered;\n7. Serious cardiac illness or medical condition;\n8. Other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness;\n9. Sensitivity to any of the study medications, any of the ingredients or excipients of these medications, or benzyl alcohol;\n10. Pregnant or lactating",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}